ICAAC 2015: Data Help Theravance's Ongoing Vibativ Relaunch
This article was originally published in Scrip
Theravance BioPharma senior vice president of development and operations Frank Pasqualone says the Vibativ (telavancin) relaunch "has gone just about as well as expected" and it has been helped by the company's growing collection of data for the intravenous antibiotic.
You may also be interested in...
Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.